Lymphoma-ka B-cell-ka ee baahsan (DLBCL), NOS, nooca hoose ee GCB, lymphoma-01 ee habdhiska neerfaha dhexe ee aasaasiga ah

Bishii Diseembar 2019, Mr. Wang, oo ah macallin ka soo jeeda Waqooyi-bari Shiinaha, ayaa bilaabay inuu la kulmo madax-xanuun. Diseembar 19, 2019, baaritaannada ogaanshaha ayaa shaaca ka qaaday kuwan soo socda: PET-CT waxay muujisay hooska cufnaanta iyadoo si weyn u kordhay dheef-shiid kiimikaadka FDG ee ku yaal dhabarka hore ee bidix iyo aagga jilibka corpus callosum (qiyaastii 3.4 * 1.9 cm, SUVmax = 34.4). Baaritaanka dhiigga iyo immunohistochemistry waxay xaqiijiyeen kala-goysyada waaweyn ee unugyada B-unugga (DLBCL, NOS, nooca hoose ee GCB), iyadoo nooca immunophenotype uu tilmaamayo Ki67(50%+), CD19(+), CD20(+), PAX5(+), CD79(+), MUM1(+), BCL(+), CD10(-/+), CD2(yar+). Falanqaynta dareeraha maskaxda ayaa muujisay 6% unugyada lymphoid-ka aan qaan-gaarin oo leh kala duwanaansho qaab-dhismeed. Baaritaanku wuxuu ahaa lymphoma-ka habdhiska neerfaha dhexe ee aasaasiga ah (DLBCL, nooca hoose ee GCB).

Ka dib markii uu online ka baaray fursadaha daaweynta, Mr. Wang wuxuu wax ka bartay awoodaha daaweynta difaaca jirka ee BIOOCUS Medical Group wuxuuna si degdeg ah u raadsaday khibradooda. Ka dib baaritaanno jireed oo dhammaystiran iyo falanqayn taxaddar leh oo ay sameeyeen kooxda khubarada isbitaalka, waxaa la go'aamiyay in Mr. Wang uu ka qaybqaato tijaabo caafimaad oo loogu talagalay daaweynta CART, gaar ahaan iyadoo la adeegsanayo unugyada CD19 CART. Wuxuu helay unugyada CD19 CAR-T ee iswada Abriil 24, 2023. Luulyo 30, 2023, waxaa lagu qiimeeyay inuu gaaray cafis dhammaystiran (CR) tan iyo markaas ayuu ku soo laabtay nolol caadi ah.